NextFin News - On February 9, 2026, victims of the Diethylstilbestrol (DES) medical scandal met with UK Health Secretary Wes Streeting to formally demand a statutory public inquiry into the long-term health impacts of the drug. The campaign group DES Justice UK (DJUK), which represents more than 500 survivors and their descendants, is seeking not only an investigation into the regulatory failures that allowed the drug to remain on the market but also the immediate implementation of a specialized NHS screening program. According to DJUK, approximately 300,000 women in the UK were prescribed DES between 1940 and 1978 to prevent miscarriages and pregnancy complications, despite evidence emerging as early as 1971 linking the synthetic hormone to rare vaginal and cervical cancers in the daughters of those who took it.
The meeting in London marks a critical turning point for a community that has spent decades in the shadows of more high-profile medical scandals. While the United States and the Netherlands have already established compensation schemes and specialized care protocols for "DES daughters" and "DES sons," the UK has lagged behind. Streeting, who previously admitted in late 2025 that the "state got it wrong," now faces the complex task of addressing a legacy of pharmaceutical harm that spans three generations. The victims, such as Susie Martin, who has undergone nearly 30 operations due to DES exposure, argue that the current lack of a centralized registry or screening protocol leaves thousands of people at risk of undiagnosed clear cell adenocarcinoma and other reproductive abnormalities.
The persistence of the DES scandal highlights a systemic failure in pharmacovigilance—the practice of monitoring the effects of medical drugs after they have been licensed. Although the U.S. Food and Drug Administration (FDA) issued a warning against DES use in pregnancy in 1971, the drug continued to be prescribed in the UK for another seven years. This delay represents a significant regulatory gap that an inquiry would likely scrutinize. From a financial and policy perspective, the demand for a public inquiry is not merely about historical accountability; it is about the future of healthcare liability. If the government concedes to a statutory inquiry, it sets a precedent for how the state manages "long-tail" medical liabilities—injuries that manifest decades after the initial exposure.
Data from international studies suggest that the health impacts of DES are not limited to the first generation. Research indicates that the granddaughters of women who took DES may also face increased risks of certain cancers and reproductive issues, suggesting epigenetic changes triggered by the drug. This multi-generational aspect complicates the potential compensation framework. Unlike the Infected Blood Inquiry or the Post Office Horizon scandal, where the victims were a finite group, the DES cohort is expanding as more descendants reach the age where symptoms manifest. For the NHS, the cost of a comprehensive screening program for hundreds of thousands of potentially affected individuals would be substantial, yet the cost of treating advanced-stage cancers resulting from a lack of screening could be even higher.
Looking forward, the outcome of the meeting between Streeting and DJUK will likely influence the broader landscape of patient safety in the UK. If a public inquiry is granted, it will likely focus on the relationship between pharmaceutical manufacturers and the regulatory bodies of the 1970s. Furthermore, as U.S. President Trump continues to emphasize deregulation in the American pharmaceutical sector, the UK’s handling of the DES legacy serves as a cautionary tale of the long-term social and economic costs of regulatory oversight failures. The trend suggests that patient advocacy groups are becoming increasingly sophisticated in using legal and media pressure to force government action, moving away from private litigation toward public-funded redress schemes. For the pharmaceutical industry, this signals a shift toward a more permanent state of accountability, where the statute of limitations is effectively bypassed by the moral weight of a public inquiry.
Explore more exclusive insights at nextfin.ai.
